1.31. Company Indemnitees has the meaning set forth in Section 9.1.
1.32. Company Terminated Product Technology means, with respect to a Terminated Product in the form and formulation such Terminated Product exists as of the applicable effective date of termination, all Patent Rights and Know-How Controlled by Company as of the effective date of termination of this Agreement that (a) was developed or invented during the Term by or on behalf of Company, its Affiliates or Sublicensees in the Development, manufacture or Commercialization of Compounds or Products and (b) is necessary for, or was otherwise used by Company, its Affiliates or Sublicensees in, the Development, manufacture or Commercialization of such Terminated Product.
1.33. Competing Product means any dual inhibitor that inhibits both of the following two biological targets: (a) BlyS and (b) APRIL in any dosage form, formulation, presentation or package configuration which is developed or commercialized in the Field.
1.34. Compound means (a) the investigational recombinant fusion protein known as atacicept, as set forth in Schedule 1.34 (Atacicept), (b) any TACI-Ig Fusion Molecule the composition of matter of which is covered by a claim of any of the ATSA Patents set forth in Schedule 1.17, and (c) any prodrug, derivative, conjugate or fusion of a compound in the preceding (a) or (b), and including any Further Linked TACI-Ig Fusion Molecule.
1.35. Confidential Information of a Party means information relating to the business, operations or products of such Party or any of its Affiliates, including this Agreement, and including any Know-How that such Party or any of its Affiliates discloses to the other Party or its respective Affiliate under this Agreement, or otherwise becomes known to the other Party or its Affiliate by virtue of this Agreement.
1.36. Controlled means, with respect to (a) Patent Rights, (b) Know-How or (c) biological, chemical or physical material, that the Party or one of its Affiliates owns or has a license or sublicense to such right, item, or material (or in the case of material, has the right to physical possession of such material) and has the ability to grant a license or sublicense to, or assign its right, title and interest in and to, such right, item or material as provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party, in particular such Third Party that has assigned or licensed such Patent Rights, Know-How or material to such Party (or any Affiliate of such Party), provided, that, other than with respect to Existing Third Party Licenses, neither Party shall be deemed to Control any Patent Rights, Know-How, or biological material, or other property right of a Third Party if access under this Agreement requires or triggers a payment obligation to such Third Party, unless the other Party agrees to reimburse the first Party for or otherwise bear the fee or charge associated therewith.
1.37. Controlling Party has the meaning set forth in Section 6.6(c).
1.38. Data Protection Law means, to the extent governing the relevant Personal Data, any data protection laws, statutes, or regulations that relate to the protection of a natural person with regard to the Processing of Personal Data in connection with this Agreement such as, to the extent applicable, the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation or GDPR).
1.39. Development means, with respect to a Compound or Product, all non-clinical research and clinical development activities conducted after filing of an IND for such Compound or Product, including toxicology, pharmacology test method development and stability testing, process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, Clinical Trials (other than post-Marketing Approval Clinical Trials), regulatory affairs, pharmacovigilance, Clinical Trial regulatory activities and obtaining and maintaining Marketing Approval. When used as a verb, Develop or Developing means to engage in Development.